20-003434 Purchase Description.pdf
PDF 198 KB Posted
- Attached to
- Induced pluripotent stem (iPS) cell-derived differentiated cells Federal contract opportunity
- Solicitation number
- NCATS-20-003434
About this file
This document outlines a pre-solicitation notice of intent for a non-competitive contract award. The National Center for Advancing Translational Sciences intends to procure various induced pluripotent stem cell-derived differentiated cells from Fujifilm Cellular Dynamics International, Inc. through a request for quotation with an expected award date of August 15, 2020. The purpose of these cells is to develop 3D tissue models of the brain for studying new therapies related to pain, opioid addiction, and overdose. Products required include iCell Astrocytes, DopaNeurons, Endothelial Cells, GABANeurons, and GlutaNeurons in specified quantities totaling over 300 units. Interested parties may submit capability statements by July 31, 2020 to be considered for a competitive procurement, otherwise the contract will be awarded non-competitively to the incumbent.
View the file
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
PURCHASE DESCRIPTION
1. Statement of Need and Purpose:
The purpose of this acquisition is to procure Induced pluripotent stem (iPS) cell-derived differentiated cells for the National Center for Advancing Translational Sciences (NCATS).
2. Background Information and Objective:
One of the greatest promises of human stem cells is to transform these early-stage cells into treatments for devastating diseases. Stem cells can potentially be used to repair damaged human tissues and to bioengineer transplantable human organs using various technologies, such as 3D printing. Using stem cells derived from another person (allogeneic transplantation) or from the patient (autologous transplantation), research efforts are underway to develop new therapies for historically difficult to treat conditions. In the past, adult stem and progenitor cells were used, but the differentiation of these cell types has proven to be difficult to control. Initial clinical trials using induced pluripotent stem (iPS) cells indicate that they are far superior for cellular therapy applications because they are better suited to scientific manipulation.
The Tissue BioPrinting Lab at NCATS is using these iPS cells to bioprint 3D tissue models of the brain to study the effects of new therapies for pain, opioid addiction and overdose. With these cells we are developing human 3D tissue models, and the only source of large amounts of human dopaminergic, gabanergic and glutaminergic is through differentiation of iPSC cells.
3. Generic Name of Product: Induced pluripotent stem (iPS) cell-derived differentiated cells
4. Purchase Description:
The items needed for our bioprinting lab are as follows:
Product Number Description
Quantity
R1092 iCell Astrocytes Kit, 01434 100 C1087 iCell DopaNeurons, 01279 [CELL ONLY] 50 C1087 iCell DopaNeurons, 01279 [CELL ONLY] 5 R1022 iCell Endothelial Cells Kit, 01434 20 R1112 iCell Endothelial Cells Kit, 11713 30 M1019 iCell Endothelial Cells Medium 20 C1012 iCell GABANeurons, 01434 [CELL ONLY] 70 C1060 iCell GlutaNeurons, 01279 [CELL ONLY] 15 C1033 iCell GlutaNeurons, 01279 [CELL ONLY] 50 R1101 iCell Retinal Pigment Epithelial Cells Kit, 01279 50
5. Salient characteristics:
These iPS cell-derived iCell® products are generated from cells, such as adult skin or blood, obtained from donors. They are delivered through an episomal reprogramming process that utilizes circular DNA vectors to deliver the pluripotency genes.
6. Quantity: See list above
7. Period of Performance: One Year from Date of Award.
File details come from the government source that posted it. Updated .